CytoMed Therapeutics (GDTC) EPS (Basic) Growth (1y) (2023 - 2025)
CytoMed Therapeutics (GDTC) EPS (Basic) Growth (1y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | -16.29% |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -35.22% |
| Dec 31, 2024 | -26.55% |
| Jun 30, 2024 | -42.55% |
| Dec 31, 2023 | 1,326.43% |
| Jun 30, 2023 | 11,094,730.40% |